Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A scheme that pays hospitals to deliver high quality care has been shown to improve the outcomes for patients with broken hips in England.

© sfam_photo/Shutterstock

Hip fractures are a major cause of death and disability among older people worldwide, with 70,000 cases every year in the UK, which cost the NHS around £2 billion.

In 2010, a Best Practice Tariff (BPT) was launched across England, which promised extra payments to hospitals for each hip fracture patient whose care satisfied six clinical standards, such as surgery within 36 hours.

Researchers from the University of Oxford and Yale University compared the data from England with that in Scotland, which does not provide BPT payments to hospitals. They found that the BPT scheme saved up to 7,600 lives in England between 2010 and 2016.

David Metcalfe of Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, said: ‘This is the first study to show that the Best Practice Tariff drove changes in practice that reduced mortality for older adults with a hip fracture in England.

‘Our research also suggests that the BPT led to generally improved standards of care for hip fracture patients. It increased the proportion of patients receiving an operation within 36 hours, shortened the average length of stay in hospital and reduced the number of patients that had to be re-admitted to hospital.

‘As it is possible that similar schemes could improve outcomes for patients and reduce costs for the NHS, we should support the controlled expansion of the BPT model to other clinical areas.’

A total of 1,037,860 adults aged over 60 were admitted to hospitals between 2000 and 2016 with a hip fracture in England, and 116,594 in Scotland. Before the BPT scheme was introduced, trends in 30-day mortality were the same in England and Scotland. However, the number of hip fracture deaths fell much more markedly in England after the BPT was introduced. A pre-existing trend towards increased numbers of patients requiring re-admission to hospital was halted after the introduction of the BPT scheme.

Similar stories

Plaster cast or metal pins to treat a broken wrist? The results are in.

An Oxford study published in The BMJ has found the use of metal K-wires (commonly known as ‘pins’) to hold broken wrist bones in place while they heal are no better than a traditional moulded plaster cast.

Professor Chris Buckley has joined the Kennedy Institute as Director of Clinical Research

Moving to the University of Oxford with the Arthritis Therapy Acceleration Programme (A-TAP) will help accelerate the discovery of new treatments for inflammatory diseases.

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters “good” macrophage behaviour within the vessel wall.

More effective treatment found for patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

NDORMS researchers honoured in the Recognition Of Distinction Scheme 2021

Sally Hopewell and John Christianson have been awarded the title of ‘Full Professor’ in the University of Oxford’s Recognition Of Distinction Scheme 2021.

New Oxford-Zeiss Centre of Excellence opens at the University of Oxford

The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.